Target Name: ZNF414
NCBI ID: G84330
Review Report on ZNF414 Target / Biomarker Content of Review Report on ZNF414 Target / Biomarker
ZNF414
Other Name(s): Zinc finger protein 414, transcript variant 1 | zinc finger protein 414 | ZNF414 variant 1 | Zinc finger protein 414 (isoform 1) | Zinc finger protein 414 | ZN414_HUMAN | ZFP414

ZNF414: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurodebris. These conditions are often treated with drugs that aim to slow down or halt the progression of neurodegeneration. However, current treatments are limited in their effectiveness and can have severe side effects. Therefore, there is a need for new and better treatments.

ZNF414: A Potential Drug Target and Biomarker

ZNF414 is a protein that is expressed in various tissues of the brain, including the nervous system. It is a member of the Zinc Finger Gene (ZNF) family, which is known for its role in the development and maintenance of neural stem cells. ZNF414 has been shown to play a role in the regulation of neural stem cell proliferation and differentiation, as well as in the regulation of neural circuit formation and plasticity.

In recent years, researchers have been interested in using ZNF414 as a potential drug target for neurodegenerative diseases. This is because the ZNF414 protein has been shown to interact with several neurotransmitters, including dopamine, which is a well-known neurotransmitter that is involved in the regulation of motivation, emotion, and memory.

ZNF414 has also been shown to interact with the protein p21, which is a well-known tumor suppressor protein that is often activated in neurodegenerative diseases. The interaction between ZNF414 and p21 suggests that ZNF414 may be a potential drug target for neurodegenerative diseases.

In addition to its potential drug target properties, ZNF414 has also been shown to be a potential biomarker for neurodegenerative diseases. This is because the levels of ZNF414 have been shown to be affected by a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

For example, studies have shown that the levels of ZNF414 are reduced in the brains of individuals with Alzheimer's disease, and that these levels are associated with the severity of the disease. Similarly, ZNF414 has been shown to be reduced in the brains of individuals with Parkinson's disease, and that these levels are associated with the severity of the disease.

In addition to its potential use as a drug target and biomarker, ZNF414 is also of interest as a potential therapeutic approach for neurodegenerative diseases. For example, researchers have shown that ZNF414 can be administered to animals with neurodegenerative diseases, such as Alzheimer's disease, and that these animals show improvements in cognitive and behavioral symptoms.

Conclusion

In conclusion, ZNF414 is a protein that has the potential to be a drug target and biomarker for neurodegenerative diseases. Its interaction with neurotransmitters, including dopamine, and its interaction with tumor suppressor proteins, such as p21, suggest that it may be a useful target for the treatment of these conditions. Furthermore, ZNF414 has also been shown to be a potential therapeutic approach for neurodegenerative diseases, as it has been shown to be effective in animal models of these conditions. Further research is needed to fully understand the potential of ZNF414 as a drug target and biomarker for neurodegenerative diseases.

Protein Name: Zinc Finger Protein 414

Functions: May be involved in transcriptional regulation

The "ZNF414 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF414 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF415 | ZNF416 | ZNF417 | ZNF418 | ZNF419 | ZNF420 | ZNF423 | ZNF425 | ZNF426 | ZNF428 | ZNF429 | ZNF43 | ZNF430 | ZNF431 | ZNF432 | ZNF433 | ZNF433-AS1 | ZNF436 | ZNF436-AS1 | ZNF438 | ZNF439 | ZNF44 | ZNF440 | ZNF441 | ZNF442 | ZNF443 | ZNF444 | ZNF445 | ZNF446 | ZNF449 | ZNF45 | ZNF451 | ZNF454 | ZNF460 | ZNF461 | ZNF462 | ZNF467 | ZNF468 | ZNF469 | ZNF470 | ZNF471 | ZNF473 | ZNF473CR | ZNF479 | ZNF48 | ZNF480 | ZNF483 | ZNF484 | ZNF485 | ZNF486 | ZNF487 | ZNF488 | ZNF490 | ZNF491 | ZNF492 | ZNF493 | ZNF496 | ZNF497 | ZNF497-AS1 | ZNF500 | ZNF501 | ZNF502 | ZNF503 | ZNF503-AS1 | ZNF503-AS2 | ZNF506 | ZNF507 | ZNF510 | ZNF511 | ZNF512 | ZNF512B | ZNF513 | ZNF514 | ZNF516 | ZNF516-DT | ZNF517 | ZNF518A | ZNF518B | ZNF519 | ZNF519P3 | ZNF521 | ZNF524 | ZNF525 | ZNF526 | ZNF527 | ZNF528 | ZNF528-AS1 | ZNF529 | ZNF529-AS1 | ZNF530 | ZNF532 | ZNF534 | ZNF536 | ZNF540 | ZNF541 | ZNF542P | ZNF543 | ZNF544 | ZNF546 | ZNF547